期刊文献+

参桃软肝丸对H_(22)肝癌荷瘤小鼠端粒酶活性及CD4^+CD25^+调节性T细胞比例的影响 被引量:4

Effects of Shentao Ruangan Pill on Telomerase Activity and Ratio of CD4^+CD25^+ Treg Cell with H_(22) Liver Cancer Cell
下载PDF
导出
摘要 目的:研究参桃软肝丸对H22肝癌荷瘤小鼠端粒酶及CD4+CD25+调节性T细胞比例的影响。方法:建立H22肝癌小鼠荷瘤模型,将32只小鼠随机分为生理盐水组(A)、参桃软肝丸正常剂量组(B)、参桃软肝丸高剂量组(C)、5Fu组(D),予相应药物干预10 d,观察小鼠的一般状态、体重、瘤重及抑瘤率、端粒酶活性及肿瘤组织中CD4+CD25+TREG细胞比例。结果:参桃软肝丸能改善小鼠一般状态;B、C、D组荷瘤小鼠体重与A组比较,差异有统计学意义(P<0.05);B、C组瘤重与A组比较,差异有统计学意义(P<0.05),D组瘤重与A组比较,差异有统计学意义(P<0.01),抑瘤率参桃软肝高剂量组与5Fu组有接近的抑瘤率,抑瘤率达38.1%。不同浓度的参桃软肝丸组肿瘤组织中端粒酶活性较生理盐水组明显降低(P<0.05),C组CD4+CD25+TREG细胞比例较A组明显降低(P<0.05)。结论:参桃软肝丸能改善小鼠一般状态,增加小鼠体重,减少瘤重,有较好的抑瘤率,其可能的作用机制与抑制端粒酶活性及降低CD4+CD25+调节性T细胞比例相关。 Objective: To discuss the effect of Shentao Ruangan PiLL on teLomerase activity and ratio of CD4+CD25+ Treg cell with H22 liver cancer cell. Methods: The H22 hepatoma tumor-bearing model was established in mice, and the 32mice were randomly divided into physiological saline group (A), Shentao Ruangan pills normal dose group (B), Shentao Ruangan pill high dose group (C) and 5Fu-group (D), 8 in each, since modeling with appropriate drug intervention for lO days; then the general condition, body weight, tumor weight and inhibition rate of tumor, telomerase activity and ratio of CD4+CD25+ Treg cell were observed. Results: Shentao Ruangan pill can improve the general condition of mice; The compassion of body weight between group A and group B as well C showed significant difference(P〈0.05); The compassion of tumor weight between group A and group B as well C showed significant difference(P〈0.05); The compassion of tumor weight between group D and group A showed significant difference(P〈0.01); With an inhibition rate of 38.1%, the high dose groups showed close inhibition rate of tumor with 5Fu group. The telomerase activity on different Shentao Ruangan dose obviously lower than the physiological saline group (P〈O.05); the ratio of CD4+CD25+Treg cell in group C obviously lower than that of the group A (P〈0.05). Conclusion: Shentao Ruangan pill can improve the general condition, increase body weight, induce tumor weight and provide good inhibition rate of tumor, and the possible mechanism is to inhibit teLomerase activity and reduce ratio of CD4+CD25+ Treg cell.
出处 《中医药导报》 2014年第2期59-61,64,共4页 Guiding Journal of Traditional Chinese Medicine and Pharmacy
基金 广东省中医药管理局科研项目(20112131)
关键词 参桃软肝丸 肝癌 H2 端粒酶活性 CD4+CD25+调节性T细胞比例 Shentao Ruangan pill Primary liver cancer H= Telomerase activity Ratio of CD4+CD25+ Treg Cell
  • 相关文献

参考文献17

二级参考文献58

共引文献63

同被引文献128

引证文献4

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部